Drug intelligence / Profile preview

BR1019-1 + BR1019-2

Development stage: Unknown
Lead developer: Boryung
Administration: Oral

Overview

BR1019-1 + BR1019-2 is a combination of two investigational drug candidates developed by Boryung Pharmaceutical for the treatment of hypertension and type 2 diabetes mellitus. Both components are classified as antihyperglycemics and antihypertensives, but their precise mechanisms of action have not been defined. The combination has reached phase III clinical trials in South Korea for both hypertension and type 2 diabetes mellitus, with studies evaluating pharmacokinetics, safety, and drug-drug interactions in healthy volunteers[1][3][4][6].

Targets

AGTR1 (Angiotensin II Type-1 receptor)DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on BR1019-1 + BR1019-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1019-1 + BR1019-2.

Explore the full profile